The Effect of Pioglitazone on Left Ventricular Mass & Function, Plasma Levels of Inflammatory, Endothelial & Thrombotic Biomarkers & Psychiatric indicators in non-Diabetic Patients with Metabolic Syndrome.
Phase of Trial: Phase IV
Latest Information Update: 24 Jun 2016
At a glance
- Drugs Pioglitazone (Primary)
- Indications Ischaemic heart disorders; Metabolic syndrome
- Focus Pharmacodynamics
- Acronyms EPICAMP
- Sponsors Osvah Pharmaceutical Company
- 09 Jun 2016 Status changed from active, no longer recruiting to completed.
- 27 Apr 2011 New trial record